Guardant Health, ConcertAI Collaborate On Agreement That Allows Biopharmaceutical Companies To Access The First Multi-Modal Real-World Data That Integrates Comprehensive Patient Electronic Medical Record Data With Both Genomic And Epigenomic Tumor Profiling Information Across The Continuum Of Cancer Care
- Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types
- Longitudinal DNA methylation measurements and comprehensive genomic profiling allow deeper insights into intrinsic and acquired resistance mechanisms
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic medical record (EMR) data with both genomic and epigenomic tumor profiling information across the continuum of cancer care.
Comment(0)
Reason For Report